Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 28;7(26):40746-40755.
doi: 10.18632/oncotarget.9442.

Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer

Bao-Tian Huang  1 , Zhu Lin  1 , Pei-Xian Lin  2 , Jia-Yang Lu  1 , Chuang-Zhen Chen  1
Affiliations

Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer

Bao-Tian Huang et al. Oncotarget. .

Abstract

This study aims to compare the radiobiological response of two stereotactic body radiotherapy (SBRT) schedules for patients with stage I peripheral non-small cell lung cancer (NSCLC) using radiobiological modeling methods. Volumetric modulated arc therapy (VMAT)-based SBRT plans were designed using two dose schedules of 1 × 34 Gy (34 Gy in 1 fraction) and 4 × 12 Gy (48 Gy in 4 fractions) for 19 patients diagnosed with primary stage I NSCLC. Dose to the gross target volume (GTV), planning target volume (PTV), lung and chest wall (CW) were converted to biologically equivalent dose in 2 Gy fraction (EQD2) for comparison. Five different radiobiological models were employed to predict the tumor control probability (TCP) value. Three additional models were utilized to estimate the normal tissue complication probability (NTCP) value for the lung and the modified equivalent uniform dose (mEUD) value to the CW. Our result indicates that the 1 × 34 Gy dose schedule provided a higher EQD2 dose to the tumor, lung and CW. Radiobiological modeling revealed that the TCP value for the tumor, NTCP value for the lung and mEUD value for the CW were 7.4% (in absolute value), 7.2% (in absolute value) and 71.8% (in relative value) higher on average, respectively, using the 1 × 34 Gy dose schedule.

Keywords: dose schedule; non-small cell lung cancer; radiobiological modeling; stereotactic body radiotherapy.

PubMed Disclaimer

Conflict of interest statement

No conflicts of interest from all participating authors.

Figures

Figure 1
Figure 1. DVH of the GTV, PTV-GTV, lung and CW after EQD2 conversion
(A) DVH of the GTV, (B) DVH of the PTV-GTV, (C) DVH of the lung, and (D) DVH of the CW. GTV = gross target volume; PTV = planning target volume; PTV-GTV = PTV minus GTV; CW = chest wall; EQD2 = biologically equivalent dose in 2 Gy fractions.
Figure 2
Figure 2. Dose distribution from the transversal, coronal and sagittal views between the two dose schedules
The dose color wash slider was set at 15 Gy for the 1 × 34 Gy schedule and 23.59 Gy for the 4 × 12 Gy schedule (the same EQD2 dose). (A) Dose distribution of the 1 × 34 Gy schedule. (B) Dose distribution of the 4 × 12 Gy schedule.
Figure 3
Figure 3. Flow chart of the radiobiological modeling
cDVH = cumulative dose volume histogram; dDVH = differential dose volume histogram; EQD2 = biologically equivalent dose in 2 Gy fractions; TCP = tumor control probability; NTCP = normal tissue complication probability; Mar = Martel model; Fen = Fenwick model; WN = Webb-Nahum model; EUD = equivalent uniform dose model; Nitin = Nitin model; LKB = Lyman-Kutcher-Burman (LKB) model; mEUD = modified equivalent uniform dose model; CW = chest wall.
See this image and copyright information in PMC

References

    1. Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, Li P, Chang JY. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66:117–125. - PubMed
    1. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund JA, Morhed E, Nilsson K, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009;27:3290–3296. - PubMed
    1. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070–1076. - PMC - PubMed
    1. Solda F, Lodge M, Ashley S, Whitington A, Goldstraw P, Brada M. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort. Radiother Oncol. 2013;109:1–7. - PubMed
    1. Zheng X, Schipper M, Kidwell K, Lin J, Reddy R, Ren Y, Chang A, Lv F, Orringer M, Spring Kong FM. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys. 2014;90:603–611. - PubMed